I'm LongbridgeAI, I can summarize articles.HeartBeam outlined Q2 progress, expanding its ECG platform from arrhythmia to heart attack detection with an imminent FDA pre-submission. The ALIGN-ACS pilot enrolled 134 patients, while the HEADSTART-ACS study passed 50% enrollment ahead of schedule. A 12-lead ECG patch prototype is complete, and commercial rollout for the cleared arrhythmia product includes initial shipments and expected larger orders in Q3 2026.
- HeartBeam outlined progress toward expanding its ECG platform from arrhythmia assessment into heart attack detection, with an FDA pre-submission planned imminently. * ALIGN-ACS chest-pain pilot enrolled 134 emergency-department patients across two sites in Belgrade; full results slated for presentation at TCT 2026. * HEADSTART-ACS, a 500-patient study backed by the Indonesian government, passed 50% enrollment in under three months, ahead of schedule. * Development update included a completed working prototype of a 12-lead ECG patch, with an ischemia-detection pilot launched in about 50 high-risk patients. * Commercial rollout for the FDA-cleared arrhythmia product included multiple practice agreements, initial shipments, patient onboarding, and expectations for larger orders in Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here